Dizal Pharmaceuticals

This early-stage study is testing a new drug called GW5282 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Researchers will enroll about 203 adults to first det…

This study is testing whether a combination of two new drugs, DZD9008 and AZD4205, is safe and effective for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation. It is for patients whose cancer has continued to grow d…

This study is comparing an experimental drug called golidocitinib against standard treatments for adults whose peripheral T-cell lymphoma has returned or not responded to prior therapy. The goal is to see if golidocitinib can better control the cancer and help patients live longe…

This is the first time researchers are testing the experimental drug DZD6008 in people. The study aims to find a safe dose and see if it can shrink tumors in adults with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The trial will…

This is the first study in people to test a new drug called DZD6008 for advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutations). The main goals are to find a safe dose and see if the drug can shrink tumors. It will enroll about 140 adults wh…

This study is testing an experimental pill called DZD8586 for adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to prior treatments. Researchers want to see if the drug can shrink tumors and understand what side effects pa…

This study is testing whether an experimental drug called DZD8586 can safely increase platelet counts in adults with immune thrombocytopenia (ITP) who haven't responded well to standard treatments. The trial will enroll 60 participants who will receive different doses of the medi…